Jul 2026· Journal of Chemical Information and Modeling· Vol 66, pp. 9743 - 9760· 0 citations· 63 references
Medicine
TL;DR
A Perspective on computational PROTAC methodologies published from 2019 to the present is presented, organizing the field into two complementary streams: constraint-driven, physics-based workflows that assemble and refine ternary complex models by enforcing geometric feasibility and evaluating pose stability using docking and molecular simulation.
Abstract
Proteolysis-targeting chimeras (PROTACs) are heterobifunctional small molecules that induce targeted protein degradation by recruiting an E3 ligase to a protein of interest. Since 2019, publication volume has accelerated, and computational methods have expanded from isolated demonstrations into practical tools for modeling PROTAC-induced ternary complexes, designing linkers, and forecasting degradation-related outcomes. Here, we present a Perspective on computational PROTAC methodologies published from 2019 to the present, organizing the field into two complementary streams: (i) constraint-driven, physics-based workflows that assemble and refine ternary complex models by enforcing geometric feasibility and evaluating pose stability using docking and molecular simulation; and (ii) data-driven workflows, including deep learning predictors and generative models that predict ternary complex structure, degradation end points, or linker chemistry from structural and assay data. We highlight representative approaches spanning restrained/tethered docking, MD-based refinement and dynamic stability scoring, coarse-grained free-energy modeling, SE(3)/E(3)-equivariant structure prediction, supervised degradation efficacy prediction, and generative linker design. We close by emphasizing persistent gaps, fragmented benchmarking, score robustness across targets and E3 ligases, and nonstandard molecular representations that currently limit generalization and reproducible, pipeline-ready deployment.
Generative kinetics is indicated as an aspirational frontier in building physically grounded and transferable models, including data availability and fidelity, the choice of inductive biases to pursue generalization, and the need for rigorous model evaluation.
Daniele Angioletti, Matteo Carli, Marco S. Nobile et al.· WIREs Computational Molecula...· 0 citations
This work presents MG2Act, a structure-independent framework that translates two-step logic into sequential cross-attention, using CRBN-mediated degradation as the most data-rich representative system.
Zhiyao Zhuang, Dan Teng, Xiao-Jing Xu et al.· bioRxiv· 0 citations
ProMeta, a prototype-based graph neural network trained through episodic meta-learning on source-E3 tasks and evaluated on held-out target-E3 tasks through support-conditioned inference, is presented as a practical framework for cross-ligase few-shot prediction under the evaluated support/query protocols.
Yuansheng Liu, Yu-Fei Ye, Tao Tang et al.· 0 citations
EvoBind-multimer is presented, a deep learning framework for the de novo design of molecular glues directly from protein sequences that generates small macrocyclic peptides that bridge user-defined protein pairs without requiring prior interface knowledge or existing ligands.
Andrä Brunner, Krzysztof Wierbiłowicz, Diandra Daumiller et al.· bioRxiv· 0 citations
Y-box binding protein 1 (YB-1) acts as a key oncoprotein, with its highly conserved cold shock domain (CSD) driving core nucleic acid-binding functions in cancer progression. Despite its therapeutic relevance, the CSD is considered “undruggable” due to the lack of a well-defined hydrophobic pocket. To overcome the limi...
Lalehan Oktay, Cem Uguz, S. Durdağı· ACS Omega· 0 citations
This review examines the comparative advantages of peptide-based architectures, including reduced molecular weight, access to challenging interfaces, and expansion of the addressable E3 ligase repertoire, against persistent translational barriers in proteolytic stability, membrane permeability, immunogenicity, and manu...
Walaa S. Aburayan, Ibrahim A. Alradwan, Beshair A. Alsaffar et al.· Pharmaceutics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.